<< Вернуться к списку статей журнала

Том 13 №4 2011 год - Нефрология и диализ

Анализ ведущих факторов прогрессирования хронической болезни почек (Обзор литературы)

Николаев А.Ю.

Аннотация: В кратком обзоре анализировались ведущие факторы прогрессирования хронической болезни почек (ХБП). Продемонстрирована прогностическая роль этиологии и клинических особенностей ХБП, ятрогенных факторов, курения, наркомании. Информативность прогнозирования ХБП повышается при сопоставлении клинических симптомов с микроальбуминурией, данными о состоянии сердечно-сосудистой системы, активности хронического воспаления и уровне белкового катаболизма (белково-энергетической недостаточности).

Для цитирования: Николаев А.Ю. Анализ ведущих факторов прогрессирования хронической болезни почек (Обзор литературы). Нефрология и диализ. 2011. 13(4):396-402. doi:

Весь текст

Ключевые слова: хроническая болезнь почек, микроальбуминурия, артериальная гипертензия, инсулинорезистентность, хроническое воспаление, ятрогения, chronic kidney disease, microalbuminuria, arterial hypertension, insulin resistance, chronic inflammation, iatrogenic factors

Список литературы:

1. Abiko H., Konta T., Hao Z. Factors correlated with plasma renin activiity in general Japanese population // Clin. Exp. Nephrol. 2009. Vol. 13. P. 130–137.
2. Agarwal R., Andersen M.J. Prognostic importance of clinic and home blood pressure recordings in patients with CKD // Kidney Int. 2006. Vol. 69. P. 406–411.
3. Akira S., Tekeda K. Toll-like receptor signaling // Nat. Rev. Immunol. 2004. Vol. 4. P. 499–511.
4. Andoh N.F., Bennet W.M. et al. Chronic Cyclosporine A nephrotoxicity // Curr. Opin. Nephrol. Hypertens. 1998. Vol. 7. P. 265–270.
5. Barsoum R.C. Hepatitis C virus: from entry to renal injury – facts and potential // Nephrol. Dial. Transplant. 2007. Vol. 22. P. 1840–1848.
6. Basi S., Lewis J.B. Microalbuminuria as a target to improve cardiovascular and renal outcome // Am. J. Kidney Dis. 2006. Vol. 47. P. 927–946.
7. Bianchi M.E. DAMPs, PAMPs and alarmins: all we need to know about danger // J. Leukoc. Biol. 2007. Vol. 81. P. 1–5.
8. Burke S.L., Evans R.G., Moretti J.L. Levels of renal and extrarenal sypathetic drive in AII-induced hypertension // Hypertension. 2008. Vol. 51. P. 878–883.
9. Calgar K., Vilmaz M.I., Sonmer A. ADMA, proteinuria and insulin resistance in non-diabetic stage I CKD // Kidney Int. 2006. Vol. 70. P. 781–787.
10. Calhoun D.A., Jones D., Textor S. Resistant Hypertension: diagnosis, evaluation and treatment // Circulation. 2008. Vol. 117. P. 510–526.
11. Chen J., Muntner P., Hamm L.L. The metabolic syndrome and chronic kidney disease in U.S. adults // Ann. Intern. Med. 2004. Vol. 140. P. 167–174.
12. Chung C.P., Oeser A., Avalos I. Cardiovascular risk scores and the presence of subclinical coronary artery atherosclerosis in women with SLE // Lupus. 2006. Vol. 15. P. 562–569.
13. Daugas E., Rougier J.P., Hill G. HAART-related nephropaties in HIV-infected patients // Kidney Int. 2005. Vol. 67. P. 393–403.
14. Dettmeyer R.B., Reuss J., Wollersen H. Heroin-associated nephropathy // Expert Opin. Drug Safety. 2005. Vol. 4. P. 19–28.
15. Dieplinger B., Mueller T., Kollerits B. Pro-A-type natriuretic peptide and pro-adrenomedullin predicts progression of CKD // Kidney Int. 2009. Vol. 75. P. 408–414.
16. Dunea G., Arruda J.A.L., Bakir A.A. Role of cocaine in ESRD in some hypertensive African-Americans // Am. J. Nephrol. 1995. Vol. 15. P. 5–9.
17. Elung-Jensen T., Starndgaard S., Kamper A.-L. Longitudinal observations on circadian BP variation in CKD stages 3–5 // Nephrol. Dial. Tranplant. 2008. Vol. 23. P. 2873–2878.
18. Eriksen B.O., Ingebretsen O.S. et al. The progression of CKD: a 10-year population-based study of the effect of gender and age // Kidney Int. 2006. Vol. 69. P. 375–382.
19. ESH-ESC Guidelines Committee. 2007 guidelines in the management of arterial hypertension // J. Hypertens. 2007. Vol. 25. P. 1105–1187.
20. Farbom P., Wahlstrand B., Almgren P. Interaction between renal function and microalbuminuria for cardiovascular risk in hypertension: NORDIL study // Hypertension. 2008. Vol. 52. P. 115–122.
21. Fontas E., van Leth F., Sabin C.A. Lipid profiles in HIV-infected patients receiving HAART // J. Infec. Dis. 2004. Vol. 189. P. 1056–1074.
22. Forman J.P., Brenner B.M. Hypertension and microalbuminuria: the bell tolls for thee // Kidney Int. 2006. Vol. 69. P. 22–28.
23. Fox C.S., Larson M.G., Leip E.P. Predictors of new-onset kidney disease in community-based population // JAMA. 2004. Vol. 291. P. 844–850.
24. Further M., Kiechl S., Mair A. Urinary albumin excretion is independently associated with carotid and femoral artery atherosclerosis in the general population // Eur. Heart J. 2005. Vol. 26. P. 279–286.
25. Gazzaruso C., Bruno R., Gazzaniti A. Hypertension among HIV-infected patients and relationship to insulin resistance and metabolic syndrome // J. Hypertens. 2003. Vol. 21. P. 1377–1382.
26. Giles J.T., Post M., Blumenthal R.S. Therapy insight: managing cardiovascular risk in patients with rheumatoid arthritis // Nat. Clin. Pract. 2006. Vol. 2. P. 320–329.
27. Goodman W.G., London G. Vascular calcification in chronic kidney disease // Am. J. Kidney Dis. 2004. Vol. 43. P. 572–579.
28. Gupta S.K., Parker R.A., Robbins G.K. The effect of HAART on albuminuria in HIV-infected persons: result from rundomized trial // Nephrol. Dial. Transplant. 2005. Vol. 20. P. 2237–2242.
29. Hermann M., Ruschitzka F. Novel anti-inflammatory drugs in hypertension // Nephrol. Dial. Transplant. 2006. Vol. 21. P. 859–864.
30. Himmelfarb J., Stevinkel P., Ikizler T.A. The elephant of uremia: oxidant stress as an unifying concept of cardiovascular disease in uremia // Kidney Int. 2002. Vol. 62. P. 1524–1528.
31. Holmberg S.P., Moorman A.C., Williamson J.M. Protease inhibitors and cardiovascular outcomes in patients with HIV-1 // Lancet. 2002. Vol. 360. P. 1747–1748.
32. Homocysteine Studies Collaboration. Homocysteine and risk of ischemic heart disease and srtoke: a meta-analysis // JAMA. 2002. Vol. 288. P. 2015–2022.
33. Horakova M., Charvat J., Hasa J. Life-threatening renal failure caused by vasomotor nephropathy associated with NSAID // Int. J. Clin. Pharm. Res. 2005. Vol. 24. P. 117–122.
34. Hsu C.Y., McCulloch C.E., Darbinian J. Elevated BP and risk of ESRD in subjects without baseline kidney disease // Arch. Intern. Med. 2005. Vol. 165. P. 923–928.
35. Jafar T.H, Stark P.C., Schmid C.H. Progression of CKD: the role of blood pressure control, proteinuria and ACE inhibition: a patient-level mеta-analysis // Ann. Intern. Med. 2003. Vol. 139. P. 244–252.
36. Jones C.A., Francis M.E., Eberhardt M.S. Microalbuminuria in the US population // Am. J. Kidney Dis. 2002. Vol. 39. P. 445–459.
37. de Jong P.E. , Gansevoort R.T. et al. Fact or fiction of the epidemic of CKD – let us not squabble about estimated GFR only, but also focus on albuminuria // Nephrol. Dial. Transplant. 2008. Vol. 23. P. 1092–1095.
38. Kalantar-Zadeh K., Ikizler T.A., Block G. Malnutrition-Inflammation complex syndrome in dialysis patients: causes and consequence // Am. J. Kidney Dis. 2003. Vol. 53. P. 864–881.
39. Kankova K., Stejskaloba A., Hertlova M. Haplotype analysis of the RAGE gene: identification of the haplotype marker for diabetes nephropathy in type 2 diabetes mellitus // Nephrol. Dial. Transplant. 2005. Vol. 20. P. 1093–1102.
40. Keane W.F., Zhang Z., Lyle P.A. Risk scores for predicting outcomes in patients with type 2 diabetes and nephropathy: the RENAAL study // Clin. J. Am. Soc. Nephrol. 2006. Vol. 1. P. 761–767.
41. Kovesdy C.P., Trivedi B.K., Kalantar-Zadeh K. Association of anemia with outcomes in men with moderate and severe chronic kidney disease // Kidney Int. 2006. Vol. 69. P. 560–564.
42. Kronborg J., Solbu M., Njolstad I. Predictors of change of estimated GFR: a population-based 7-year follow-up from Tromso study // Nephrol. Dial. Transplant. 2008. Vol. 23. P. 2818–1826.
43. Lai F.M., To K.F., Wang A.Y. Hepatitis B virus-related nephropathy and lupus nephritis // Mod. Pathol. 2000. Vol. 13. P. 166–172.
44. Lewelyn D.E., Garsia-Puig J. How different urinary albumin excretion rates can predict progression to nephropathy and the effect of the treatment in hypertensive diabetes // J. Renin Angiotensin Aldosterone System. 2004. Vol. 5. P. 141–145.
45. Liberopoulos E., Siamopoulos K., Elisaf M. Apolipoprotein E and renal disease // Am. J. Kidney Dis. 2004. Vol. 43. P. 223–233.
46. Lin J., Hu F.B., Rifai N. The association of serum lipids and inflammatory biomarkers with renal function in men with type 2 diabetes mellitus // Kidney Int. 2006. Vol. 69. P. 336–342.
47. Locatelli F., Canaud B., Eckardt K.-U. The importance of diabetic nephropathy in current nephrological practice // Nephrol. Dial. Transplant. 2003. Vol. 18. P. 1716–1725.
48. Lopez B., Gonzalez A., Hermida N. Myocardial fibrosis in CKD: potential benefits of torasemide // Kidney Int. 2008. Vol. 74. Suppl. 111. S19–S23.
49. Menon V., Greene T., Wang X. C-Reactive protein and albumin as predictors of all-cause and cardiovascular mortality in CKD // Kidney Int. 2005. Vol. 68. P. 766–772.
50. Methe H., Weis M., et al. Atherogenesis and inflammation – was Virchow right? // Nephrol. Dial. Transplant. 2007. Vol. 22. P. 1823–1827.
51. Meyers C.M., Seef L.B. Stehman-Breen C.O. Hepatitis C and renal disease: an update // Am. J. Kidney Dis. 2003. Vol. 42. P. 631–657.
52. Meyrier A., Noel L.U., Aurch P. Long-term renal tolerance of cyclosporine A treatment in adult idiopathic nephroitic syndrome // Kidney Int. 1994. Vol. 45. P. 1446–1456.
53. Molzahn M., Pommer W., De Broe M.E. Analgesic nephropathy / Oxford texbook of Clinical Nephrology/ edit. A.M. Davison, J.S. Cameron, J.P. Grunfeld. 1998. P. 1129–1146.
54. Moreland L.W., O Dell J.R. Glucocorticoids and rheumatoid arthritis. Back to the future // Arthritis Rheum. 2002. Vol. 46. P. 2553–2663.
55. Morse C.G., Kovacs J.A. Metabolic and sceletal complications of HIV infection: the price of success // JAMA. 2006. Vol. 296. P. 844–854.
56. Mukherjee D., Nissen S.E. Risk of cardiovascular events associated with selective COX-2 inhibitors // JAMA. 2001. Vol. 286. P. 954–959.
57. Nishimura M., Hashimoto T., Kobayashi H. Close association of Chlamydia pneumonia IgA seropositivity by ELISA with the presence of coronary artery stenosis in haemodialysis patientls // Nephrol. Dial. Transplant. 2005. Vol. 20. P. 1944–1950.
58. Nwankwo E., Bello A.K., El Nahas A.M. Chronic Kidney Disease: stemming the global tide // Am. J. Kidney Dis. 2005. Vol. 45. P. 201–208.
59. Odamaki M., Furuya R., Kunimara Y. Association between plasma adiponectin and visceral fat accumulation in hemodialysis patients // Nephron. 2006. Vol. 102. P. 8–13.
60. Orth S.R., Schroeder T., Ritz E. Effect of smoking on renal function in patients with type 1 and type 2 diabetes mellitus // Nephrol. Dial. Transplant. 2005. Vol. 20. P. 2414–2419.
61. Ozsoy R.C., van der Steeg W.A., Kastelein J.Y.P. Dyslipidaemia as predictor of progressive renal failure and the impact of treatment with atorvastastin // Nephrol. Dial. Transplant. 2007. Vol. 22. P. 1578–1586.
62. Pauletto P., Rattazzi M., et al. Inflammation and hypertension: the search for a link // Nephrol. Dial. Transplant. 2006. Vol. 21. P. 850–853.
63. Pontremoli R., Leoncini G., Ravera M. Microalbuminuria, cardiovasacular and renal risk in primary hypertension // J. Am. Soc. Nephrol. 2002. Vol. 13. Suppl. 3. S169–S172.
64. Ravani P. Tripepu G., Mallberti F. ADMA predicts progression to dialysis and death in patients with CKD: a competing risks modeling approach // J. Am. Soc. Nephrol. 2005. Vol. 16. P. 2449–2455.
65. Retnakaran R., Cull C.A., Thorne K.L. Risk factors for renal dysfunction in type 2 diabetes: UK prospective dibetes study // Diabetes. 2006. Vol. 55. P. 1832–1839.
66. Rodriguez-Iturbe B., Johnson R.J. Role of inflammatory cells in the kidney in the induction and maintenance of hypertension // Nephrol. Dial. Transplant. 2006. Vol. 21. P. 260–263.
67. Roling J., Schmidt H., Fischreder M. HIV-associated renal disease and HAART-induced nephropathy // Clin. Infect. Dis. 2006. Vol. 42. P. 1488–1495.
68. Sherer Y., Shoenfeld I. Mechanisms of disease: atherosclerosis in autoimmume diseases // Nat. Clin. Pract. 2006. Vol. 2. P. 99–106.
69. Short R.A., Johnson R.J., Tuttle K.R. Uric acid, microalbuminuria and cardiovascilar disease in high-risk patients // Am. J. Nephrol. 2005. Vol. 25. P. 36–44.
70. Staessen J.A., Wang J.G., Thijs L. Cardiovascular protection and blood pressure reduction: a meta-analysis // Lancet. 2001. Vol. 358. P. 1305–1315.
71. Stenvinkel P. C-reactive protein – does it promote vascular disease // Nephrol. Dial. Transplant. 2006. Vol. 21. P. 2718–2720.
72. Stewart J.H., McCredie M.R., Williams S.M. The enigma of hypertensive ESRD: observations on incidence and trends in 18 European, Canadian and Asian-Pacific populations, 1998 to 2002 // Am. J. Kidney Dis. 2006. Vol. 48. P. 183–191.
73. Stuveling E.M., Bakker S.J.L., Hillege H.L. Biochemical risk markers: a novel area for prediction of renal risk? // Nephrol. Dial. Transplant. 2005. Vol. 20. P. 497–508.
74. Tanaka H., Shiohira Y., Uezi Y. Metabolic syndrome and chronic kidney disease in Okinawa, Japan // Kidney Int. 2006. Vol. 69. P. 369–374.
75. Thomas M.C. Anemia in diabetes: marker or mediator of microvascular disease ? // Nat. Clin. Proc. Nephrol. 2007. Vol. 3. P. 20–30.
76. Tylicki L., Puttinger H., Rutkowski P. Smoking as a risk factor for renal injury in essential hypertension // Nephron. 2006. Vol. 103. P. 121–128.
77. Vanholder R., Massy Z., Argiles A. Chronic kidney disease as a cause of cardiovascular morbidity and mortality // Nephrol. Dial. Transplant. 2005. Vol. 20. P. 1048–1056.
78. Vogt L., de Zeeuw D., Woittiez A.J. Slective COX-2 inhibition reduces proteinuria in renal patients // Nephrol. Dial. Transplant. 2009. Vol. 24. P. 1182–1189.
79. Vupputuri S. Batuman V., Muntner P. The risk for mild kidney function decline associated with illicit drugs use among hypertensuve men // Am. J. Kidney Dis. 2004. Vol. 43. P. 629–635.
80. Weis M., von Scheidt W. Coronary artery disease in the transplant heart // Annual. Rev. Med. 2000. Vol. 51. P. 81–100.
81. Yokoyama H., Sone H., Oishi M. Prevalence of albuminuria and renal insufficiency in type 2 diabetes: JDDM15 study // Nephrol. Dial. Transplant. 2009. Vol. 24. P. 1212–1219.

Другие статьи по теме

• Взаимосвязь фибрилляции предсердий и дисфункции почек у больных с хронической сердечной недостаточностью
• Функциональное состояние почек, экскреция альбумина с мочой и почечная гемодинамика у больных с хронической сердечной недостаточностью (ХСН)
• Артериальная гипертензия у детей, перенесших гемолитико-уремический синдром
• Состояние когнитивных функций у пациентов пожилого и старческого возраста с артериальной гипертензией в зависимости от наличия сопутствующей хронической болезни почек С3а и С3б стадии